Macular oedema (diabetic) - aflibercept: committee papers

01. NICE's response to comments on the Appraisal Consultation Document (ACD)

02. Consultee comments on the ACD - Bayer

03. commentator comments on the ACD - Alimera Sciences

04. Commentator comments on the ACD - Novartis

05. New evidence submitted at ACD consultation by Bayer

06. ERG critique of Bayer new evidence

This page was last updated: 28 May 2015